Wegovy vs Zepbound
A side-by-side look at two weight management medications advertised on TV. Informational only — not medical advice.
| US Wegovy | US Zepbound | |
|---|---|---|
| Generic name | semaglutide | tirzepatide |
| Drug class | GLP-1 Receptor Agonist | GIP/GLP-1 Receptor Agonist |
| Treats | Chronic weight management, cardiovascular risk reduction | Chronic weight management, obstructive sleep apnea |
| Category | Weight Management | Weight Management |
| Manufacturer | Novo Nordisk | Eli Lilly |
| Year approved | 2021 | 2023 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $380M | $300M |
| Common side effects | Nausea, Diarrhea, Vomiting, Constipation | Nausea, Diarrhea, Vomiting, Constipation |
Frequently asked questions
Is Wegovy or Zepbound better?
Neither is universally "better." Wegovy (semaglutide) and Zepbound (tirzepatide) are both used for weight management, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Wegovy and Zepbound?
Wegovy is a GLP-1 Receptor Agonist made by Novo Nordisk, while Zepbound is a GIP/GLP-1 Receptor Agonist made by Eli Lilly. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Wegovy has the larger estimated TV advertising budget of the two.